Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.
Nicolas FissoloLaura Cervera-CarlesLuisa María Villar GuimeransAlberto LleóJordi ClarimónJelena DrulovicIrena DujmovicMargarete Maria VoortmanMichael KhalilElia GilLaura NavarroJose Carlos Álvarez-CermeñoXavier MontalbanManuel ComabellaPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2018)
The role of cerebrospinal fluid (CSF) mitochondrial DNA (mtDNA) levels as biomarker in multiple sclerosis (MS) is unknown. We determined CSF mtDNA levels in a cohort of 237 individuals, including patients with MS and clinically isolated syndrome (CIS), inflammatory and non-inflammatory neurological controls, and cognitively healthy controls (HC). mtDNA concentration was measured by droplet digital polymerase chain reaction. CSF mtDNA levels were increased in all pathological conditions compared with HC, though no differences were observed between relapse-onset and progressive MS clinical forms, CIS patients and neurological controls. These findings do not support the determination of CSF mtDNA levels as a useful biomarker in MS clinical practice.
Keyphrases
- mitochondrial dna
- copy number
- multiple sclerosis
- cerebrospinal fluid
- mass spectrometry
- ms ms
- end stage renal disease
- genome wide
- white matter
- dna methylation
- newly diagnosed
- ejection fraction
- chronic kidney disease
- gene expression
- prognostic factors
- high resolution
- single cell
- high throughput
- subarachnoid hemorrhage
- patient reported